Vera Therapeutics initiated with a Buy at BofA

BofA initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $48 price target The firm sees potential upside in shares coming from its lead drug, atacicept, launching into a multibillion-dollar market, the analyst tells investors. The firm notes that its $3B nominal peak sales forecast for 2037 reflects its view that atacicept could offer a favorable treatment option in multiple autoimmune disorders, pending future clinical data validation.